Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ceftolozane/Tazobactam treatment for patients with hospital-acquired and ventilatory-associated bacterial pneumonia in Canada in 2022-2024: results from the CLEAR registry.
Zhanel GG, Dhami R, Baxter M, Wong M, Mirzanejad Y, Kosar J, Cervera C, Irfan N, Borgia S, Serebryanskyy A, Ariano R, Savoie M, Tascini C, Walkty A, Karlowsky JA. Zhanel GG, et al. Among authors: kosar j. Expert Rev Anti Infect Ther. 2024 Sep 26:1-8. doi: 10.1080/14787210.2024.2405930. Online ahead of print. Expert Rev Anti Infect Ther. 2024. PMID: 39324660
How is ceftobiprole used in Canada: the CLEAR study final results.
Zhanel GG, Kosar J, Baxter M, Dhami R, Borgia S, Irfan N, Dow G, Dube M, von den Baumen TR, Tascini C, Lee A, Chagla Z, Girouard G, Bourassa-Blanchette S, Wu M, Keynan Y, Walkty A, Karlowsky JA. Zhanel GG, et al. Among authors: kosar j. Expert Rev Anti Infect Ther. 2024 Aug;22(8):681-688. doi: 10.1080/14787210.2024.2374280. Epub 2024 Jul 15. Expert Rev Anti Infect Ther. 2024. PMID: 39008122
Real-life experience with IV fosfomycin in Canada: Results from the Canadian LEadership on Antimicrobial Real-life usage (CLEAR) registry.
Zhanel G, Baxter M, Wong M, Mirzanejad Y, Lee A, Dhami R, Kosar J, Werry D, Irfan N, Tessier JF, Girourd G, Tascini C, von den Baumen TR, Walkty A, Karlowsky JA. Zhanel G, et al. Among authors: kosar j. J Glob Antimicrob Resist. 2023 Jun;33:171-176. doi: 10.1016/j.jgar.2023.03.010. Epub 2023 Apr 6. J Glob Antimicrob Resist. 2023. PMID: 37030573 Free article.
The 2018 Global Point Prevalence Survey of antimicrobial consumption and resistance in 47 Canadian hospitals: a cross-sectional survey.
German GJ, Frenette C, Caissy JA, Grant J, Lefebvre MA, Mertz D, Lutes S, McGeer A, Roberts J, Afra K, Valiquette L, Émond Y, Carrier M, Lauzon-Laurin A, Nguyen TT, Al-Bachari H, Kosar J, Peermohamed S, Science M, Landry D, MacLaggan T, Daley P, McDonald G, Ang A, Chang S, Lin YC, Tong B, Malfair S, Leung V, Katz K, Pauwels I, Goossens H, Versporten A, Conly J, Thirion DJG. German GJ, et al. Among authors: kosar j. CMAJ Open. 2021 Dec 21;9(4):E1242-E1251. doi: 10.9778/cmajo.20200274. Print 2021 Oct-Dec. CMAJ Open. 2021. PMID: 34933882 Free PMC article.
Real-life experience with ceftolozane/tazobactam in Canada: results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry.
Zhanel GG, Dhami R, Baxter M, Kosar J, Cervera C, Irfan N, Zvonar R, Borgia S, Tessier JF, Dow G, Ariano R, Dube M, Savoie M, Bassetti M, Walkty A, Karlowsky JA. Zhanel GG, et al. Among authors: kosar j. J Glob Antimicrob Resist. 2021 Jun;25:346-350. doi: 10.1016/j.jgar.2021.03.025. Epub 2021 May 11. J Glob Antimicrob Resist. 2021. PMID: 33984530 Free article.
Real-life experience with ceftobiprole in Canada: Results from the CLEAR (CanadianLEadership onAntimicrobialReal-life usage) registry.
Zhanel GG, Kosar J, Baxter M, Dhami R, Borgia S, Irfan N, MacDonald KS, Dow G, Lagacé-Wiens P, Dube M, Bergevin M, Tascini C, Keynan Y, Walkty A, Karlowsky J. Zhanel GG, et al. Among authors: kosar j. J Glob Antimicrob Resist. 2021 Mar;24:335-339. doi: 10.1016/j.jgar.2021.01.014. Epub 2021 Feb 1. J Glob Antimicrob Resist. 2021. PMID: 33540083 Free article.
Antimicrobial use among adult inpatients at hospital sites within the Canadian Nosocomial Infection Surveillance Program: 2009 to 2016.
Rudnick W, Science M, Thirion DJG, Abdesselam K, Choi KB, Pelude L, Amaratunga K, Comeau JL, Dalton B, Delport J, Dhami R, Embree J, Émond Y, Evans G, Frenette C, Fryters S, German G, Grant JM, Happe J, Katz K, Kibsey P, Kosar J, Langley JM, Lee BE, Lefebvre MA, Leis JA, McGeer A, Neville HL, Simor A, Slayter K, Suh KN, Tse-Chang A, Weiss K, Conly J; Canadian Nosocomial Infection Surveillance Program. Rudnick W, et al. Among authors: kosar j. Antimicrob Resist Infect Control. 2020 Feb 13;9(1):32. doi: 10.1186/s13756-020-0684-2. Antimicrob Resist Infect Control. 2020. PMID: 32054539 Free PMC article.
13 results